{"id":"W2129277265","doi":"10.1200/jco.2012.42.2444","title":"Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Genentech; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; IC Design Education Center; Biogen","keywords":"Medicine; Vincristine; Mantle cell lymphoma; Rituximab; Cyclophosphamide; Ibritumomab tiuxetan; Radioimmunotherapy; Internal medicine; Oncology; Phases of clinical research; Doxorubicin; Prednisone; Lymphoma; Chemotherapy; Monoclonal antibody; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003361647,0.001777884,0.002335548,0.0004498419,0.0004955041,0.0008583676,0.001407973,0.00155068,0.002548446],"category_scores_gemma":[0.001339779,0.0007681897,0.001374294,0.0004824242,0.001372484,0.0008227528,0.0004449295,0.002667935,0.0009233741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106352,"about_ca_system_score_gemma":0.00248335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001361473,"about_ca_topic_score_gemma":0.002042142,"domain_scores_codex":[0.9989182,0.0006944176,0.00004730242,0.0001420174,0.00007215392,0.0001260215],"domain_scores_gemma":[0.9985887,0.0002246891,0.0002798776,0.0001498945,0.0000800186,0.0006768323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7769533,0.1485083,0.0149302,0.0003535029,0.00133569,0.0002649443,0.0002755595,0.002340737,0.02164039,0.0001641488,0.001127,0.03210618],"study_design_scores_gemma":[0.5723832,0.4127003,0.0112346,0.0000180063,0.000262239,0.000126371,0.0000413555,0.0007454949,0.001652279,0.0000591302,0.0007612591,0.00001590334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953061,0.0005493079,0.0004124543,0.0001445274,0.000081393,0.002636793,0.0003284383,0.00003500279,0.0005060356],"genre_scores_gemma":[0.9903709,0.0008807628,0.00162707,0.0006248028,0.0001852578,0.003667795,0.001513894,0.00001790782,0.001111721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003361647,"threshold_uncertainty_score":0.01777828,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05367725134889992,"score_gpt":0.4188483089192925,"score_spread":0.3651710575703926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}